CDK5 activates Hippo signaling to confer resistance to radiotherapy via upregulating TAZ in lung cancer
Ontology highlight
ABSTRACT: Tumor resistance to radiotherapy is a therapeutic challenge in the treatment of patients with lung cancer. Cyclin-dependent kinase 5 (CDK5) has been proposed to participate in cell proliferation, migration and invasion; drug resistance; and immune evasion. However, the functions and regulatory mechanisms of CDK5 in lung cancer radioresistance have not been investigated.SiRNAs and ShRNAs were used to knock down CDK5 in A549 and H1299 cells. The effects of CDK5 depletion on the tumorigenic behaviors of non-small cell lung cancer (NSCLC) cells were evaluated in vitro and in vivo. Gene expression was examined by RNA-seq and quantitative real-time PCR.
ORGANISM(S): Homo sapiens
PROVIDER: GSE148532 | GEO | 2021/04/30
REPOSITORIES: GEO
ACCESS DATA